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ABSTRACT
Diabetes mellitus is a major 
health problem associated with 
microvascular and macrovascu-
lar complications, leading to in-
creased morbidity and mortality. 
It is rapidly growing worldwide 
with a huge economical and so-
cial burden. Although prevention 
and treatment of diabetes and its 
complications play a key role in 
reducing its morbidity and mor-
tality, they require an integrated 
team approach at national and 
international levels. Early diagno-
sis, correct treatment, and effec-
tive follow-up are essential in any 
health care system to prevent 
complications of diabetes and en-
sure patients’ well being.
INTRODUCTION
Diabetes Mellitus (DM) is a rapidly 
growing chronic and multifactorial 
disease with a worldwide projec-
tion of 324 million diabetics by the 
year 2025 (1). In Africa, the prev-
alence of diabetes is expected to 
rise by 98%, from 13.6 million at 
2003 to 26.9 million at 2025. A 
similar increase (97%) is expect-
ed in the Middle East region with 
an estimated prevalence of 35.9 
million diabetics by 2025.
This emphasizes the health and 
economic threat diabetes poses 
in these countries as well as the 
importance of having recognized 
guidelines for the management of 
diabetes in order to prevent the     www.ljm.org.ly   
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complications and ensure a nor-
mal quality of life to the patients. 
The prevalence of DM in Libya is 
not precisely known; although it 
has been estimated to be as high 
as 14.1% (prevalence of total glu-
cose intolerance was 22.6%) (2). 
In this article, we brieﬂy discuss 
the basic management of diabe-
tes in adults directed mainly to 
medical students and junior col-
leagues. However, the different 
phases (and complications) of 
diabetes are beyond the scope of 
this review. 
Is it diabetes? Deﬁnite diagnos-
tic criteria are crucial for identi-
fying subjects with pre-diabetes 
[impaired fasting diabetes (IFG) 
and impaired glucose tolerance 
(IGT)] or diabetes. One casual 
measurement of blood glucose 
in a patient with symptoms and 
signs of diabetes, or two random 
postprandial measurements, are 
enough to make the diagnosis. 
However, oral glucose tolerance 
test (OGTT) is still the standard 
diagnostic and screening method 
for DM. The diagnostic criteria, 
(table 1) (3) uses plasma samples 
and whole blood samples. Whole 
blood samples, if used, will give ~ 
11% lower values. One may also 
consider the differences between 
values obtained from capillary or 
venous samples, as venous sam-
ples have lower postprandial val-
ues.
Meeting the patient:
At diagnosis:
History: The most common symp-
toms are polyuria, polydipsia, and 
fatigue. The severity and duration 
of symptoms can help to differen-
tiate type 1 from type 2 clinically, 
as the latter has a longer dura-
tion of onset (months) compared 
to type 1 (weeks). Strong family 
history and minimal weight loss 
are in favor of type 2. As ~ 20% 
of type 2 diabetics have a com-
plication already at diagnosis, 
one should ask about symptoms 
of complications e.g. numbness 
and sensation loss in feet, claudi-
catio complaints, impaired vision 
(can also be caused by hypergly-
cemia), etc. Few patients present 
with infection at diagnosis or ke-
toacidosis.
Examination: Patients should be 
examined for signs of dehydra-
tion. Height, weight, BMI, rest 
pulse, and sitting blood pres-
sure should be measured. Signs 
of complications should also be 
examined: these include blood 
pressures while lying down and 
standing up to test for orthostatic 
drop, foot pulses, vibration sense, L
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touch sense, and reﬂexes in lower 
extremities as well as fundal ex-
amination (by ophthalmologist).
Laboratory investigations:
Plasma glucose to conﬁrm diag-
nosis (table 1).
Urine examination for ketonuria 
in type 1. If the test is positive, 
metabolic acidosis should be ex-
cluded.
C-peptide: Normal or high value 
indicates type 2, while low or im-
measurable value indicates insu-
lin deﬁciency (e.g. type 1).
Antibodies: e.g. GAD65Ab 
(glutamic acid decarboxylase-65 
antibody) and ICA-ab (islet cell 
antibody), their presence indi-
cates autoimmunity as in type 1.
HbA1c, serum creatinin, serum 
lipids (total cholesterol, LDL-cho-
lesterol, HDL-cholesterol and trig-
lycerides) and urinary albumin.
Annual follow up:
History: Ask for symptoms of hy-
perglycemia or hypoglycemia, 
blood glucose values from pa-
tients self controls, symptoms of 
complications, and actual treat-
ment and doses. Weight loss in 
uncontrolled diabetic may indicate 
the need for insulin treatment.
Examination: the patient should 
be examined for BMI, rest pulse, 
blood pressure (lying and stand-
ing), and signs of complications. 
Fundal examination by an oph-
thalmologist must be performed 
annually for patients with type 1, 
and biannually for patients with 
type 2. When retinopathy chang-
es are detected, examination is 
repeated more often in accord-
ance with an ophthalmologist’s 
recommendations.
Laboratory investigations: HbA1c 
(4 times/yr), serum creatinin, se-
rum lipids, and urinary albumin.
HbA1c (4 times/yr), serum creat-
inin, serum lipids, and urinary al-
bumin.
ECG: for all patients with type 2 
diabetes and patients with type 
1 diabetes at 40 years or older 
with at least one cardiovascular 
risk factor (hypertension, hyperli-
pidemia, albuminuria, smoking or 
ischemic heart disease).
Current treatment of diabetes 
mellitus:
Patient education: in all types of 
diabetes.Libyan Journal of Medicine, Volume 1, 2006
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Diet treatment: in all types of dia-
betes.
Physical training: in all types of 
diabetes. It reduces weight, cen-
tral obesity, and blood lipids while 
improving insulin sensitivity, thus 
improving plasma glucose.
Stop smoking: in all types of dia-
betes.
Acetylsalicylic acid: 75-160mg 
daily should be considered for all 
patients with type 2 DM, and pa-
tients with type 1 DM older than 
40 years with at least one cardio-
vascular risk factor. 
Oral antidiabetics: 
Insulin secretion stimulators:
Sulphonylureas: An old class, 
less often used nowadays due to 
risk of hypoglycemia. They are 
long acting drugs with less effect 
on post-prandial hyperglycemia. 
Examples of this class: Glibencla-
mide (Daonil), Glipizide (Mindiab) 
and Glimepiride (Amaryl).
Metiglinides: A relatively new 
group of drugs. They are preferred 
over sulphonylureas, as they 
have shorter duration of action, 
pose less risk for hypoglycemia, 
and are more effective on post-
prandial hyperglycemia, even 
when pre-prandial glucose values 
are acceptable. They are given 
before meals. Examples of this 
class: Repaglinide (Novonorm) 
and Nateglinide (Starlix). 
 
Insulin sensitizers:
Biguanides: Metformin is the only 
drug in this group. It is widely 
used and considered ﬁrst line 
treatment in DM type 2. Gastroin-
testinal side effects are common 
but avoidable by slow up titration 
of doses.
Thiazolidinediones (Glitazones): 
Examples of this class: Rosiglita-
zone (Avandia) and Pioglitazone 
(Actos). Side effects are weight 
gain and ﬂuid retention. Maculo-
edema has also been reported. 
α glucosidase inhibitor: 
Acarbose (Glucobay): It has lim-
ited use due to gastrointestinal 
side effects.
Insulin:  
Short acting human insulin: its 
use is mostly limited now to acute 
situations where intravenous in-
sulin infusion or intramuscular 
injections are needed e.g. Dia-
betic ketoacidosis or hyperosmo-
lar non-ketotic coma. Example of     www.ljm.org.ly   
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this class: Actrapid.
Rapid acting insulin analogues: 
the insulins of choice at meal time, 
they have less hypoglycemic risk 
and better effect on post-prandial 
hyperglycemia. Examples of this 
class: insulin Aspart (Novorapid) 
and insulin Lispro (Humalog).
Intermediate acting insulins: are 
used as base insulin. Examples 
of this class: Human insulin: In-
sulatard and Humulin NPH, insu-
lin analog: insulin Detemir (Lev-
emir).
Long acting: insulin analog: an 
example of this class is insulin 
Glargine (Lantus). It has less risk 
for hypoglycemia and more stable 
plasma distribution with almost 
peakless levels after injections.
Mixed insulins: insulin analogues, 
examples are Novomix 30, Hu-
malog mix 25, and Humalog mix 
50. The previously widely used 
mixed human insulins (e.g. insu-
lin Mixtard) are rarely used since 
the introduction of mixed insulin 
analogues.
Insulin inhalers: an example of this 
class is Exubera, human insulin. 
It s approved in Europe and USA, 
and expected to be available for 
clinical use in Sweden in autumn 
2006. It is a rapid acting insulin to 
be given at meal times, for type 
1 and 2 diabetics. The use will 
probably be initially restricted to 
patients with type 2 diabetes who 
are badly controlled on all possi-
ble standard injection therapies. 
However, it should be used with 
caution until enough experience 
and more studies are available 
on this kind of insulin therapy.
Future classes:
Glucagon like peptide 1 (GLP-
1) analogs, (example: Liraglu-
tide, Novonordisk) and Dipeptidyl 
peptidase 4 (DPP-4) inhibitors 
(example: Sitagliptin, Merck and 
Vildagliptin, Novartis). They act 
mainly by stimulating insulin se-
cretion. 
Drug treatment strategy:
Type 1 diabetes (absolute insulin 
deﬁciency):
Multiple insulin injections: 
Rapid acting insulin (Novorapid/
Humalog) at meal time and Lan-
tus once at night as base insulin 
is the mostly used regimen. Lan-
tus can also be given at any time 
during the day e.g. morning, at 
lunch, or in the evening. As al-
ternatives to Lantus, Insulatard 
or Detemir can be used once or Libyan Journal of Medicine, Volume 1, 2006
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twice daily. Regular blood sugar 
self controls are strongly recom-
mended. A whole day proﬁle (at 
breakfast, lunch, evenings meal 
and bedtime) 1-2 times/week is 
preferred.
In cases with insulin deﬁciency in 
elderly patients [DM type 1, latent 
autoimmune diabetes in adults 
(LADA) or secondary diabetes to 
pancreas diseases], a more sim-
ple insulin regimen can be used 
instead, e.g. 2 doses of mixed in-
sulin daily. 
Insulin pump: Continuous sub-
cutaneous insulin infusion (CSII) 
can be considered in insulin de-
pendent patients with good com-
pliance and sufﬁcient education.
TYPE 2 DIABETES (RELATIVE-
LY PRESERVED INSULIN SE-
CRETION): 
Diet and physical training: is 
the ﬁrst line treatment. Regular 
blood sugar self controls should 
be used. If blood glucose is still 
not controlled, add treatment in 
next step.
Oral treatment: Patient with 
overweight: Metformin as initial 
therapy can be used in increasing 
dose to avoid side effects (alter-
native glitazone e.g. Avandia or 
Actos). If blood glucose is still not 
well controlled, add Novonorm or 
Starlix. Patients with normal BMI: 
Novonorm or Starlix can be used 
initially. They can be combined 
with Metformin or glitazone.
If still not controlled:
Insulin treatment: Base insu-
lin can be added to ongoing oral 
treatment, ex: Lantus or Insula-
tard once daily. Glitazone treat-
ment is contraindicated in combi-
nation with insulin therapy. Mixed 
insulin, ex: Novomix 30 or Huma-
log mix 25, can be given before 
breakfast and dinner. Patient can 
continue on Metformin while insu-
lin secretion stimulators are usu-
ally (but not always) discontinued. 
In severe insulin resistant cases 
requiring large insulin doses, mul-
tiple insulin injections are used as 
those in type 1 diabetes, usually 
in combination with Metformin.
Goals and limits of treatment: 
Lowering blood glucose and 
HbA1c is crucial to reduce the 
risk for vascular complications 
in patients with type 1 (4, 5) and 
type 2 diabetes (6, 7). The goals 
of treatment summarized in table 
2 are according to recommen-
dations of the American Diabe-
tes Association (8) and national 
guidelines in Sweden (9). The 
aims of these guidelines are to     www.ljm.org.ly   
page
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prevent the complications and 
ensure the well-being of patients. 
These goals, especially blood glu-
cose and HbA1c, should be indi-
vidualized depending on patient’s 
age, type of diabetes, presence 
of complications, multiorgan and 
psychiatric disease. It should not 
take a long time (in type 2, insulin 
therapy should be reached within 
5 years after diagnosis) to reduce 
the HbA1c to the recommended 
level. The lowest possible HbA1c 
that can be reached, without seri-
ous hypoglycemic events or side 
effects is probably the best deﬁ-
nition of goal HbA1c in term of 
individualization the goal. In eld-
erly patients, tight control of blood 
glucose may not be recommend-
ed due to high risk of hypoglyc-
emia. Other parameters are as 
important as HbA1c regarding 
the risk for vascular complica-
tions. Patients with 
well controlled blood 
pressure have lower 
risk for myocardial in-
farction and stroke. A 
1% reduction in serum 
LDL-cholesterol re-
duces the risk for total 
mortality by 12%.
There is an ongoing 
discussion in Swe-
den in order to lower 
the level of treatment 
goals: HbA1c 6.8% 
in type 1, HbA1c 5.9-
6.8% in type 2 (lower 
HbA1c in type 2 due 
to less risk for hy-
poglycemia), serum 
total cholesterol <170 
mg/dl and blood pres-
sure in patients with nephropathy 
<120/70 mmHg. The reason for 
this additional tightening of treat-
ment goals is the occurrence of 
complications at low HbA1c lev-
els (>5.9%).  
To apply these goals is practi-Libyan Journal of Medicine, Volume 1, 2006
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cally difﬁcult, but the patient is 
ultimately the beneﬁciary. Again, 
individualization of the treatment 
is of extreme importance in the 
management of patients with dia-
betes. The self-control of blood 
glucose by patients and educa-
tion of both patients and diabetes 
health care teams are the most 
important steps to be considered 
by colleagues and authorities to 
improve the diabetes care.
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